Survivors of Ebola virus disease (EVD) in Liberia had a higher prevalence of certain health issues — including uveitis (eye redness and pain), abdominal, chest, neurologic, and musculoskeletal abnormalities upon physical exam — when compared to a control group of household and community members who did not have a history of EVD, according to findings from an ongoing study published in the New England Journal of Medicine. However, even participants in the control group experienced a relatively high burden of health issues overall.
The study began in 2015 and is following participants for five years. It is being conducted by the Partnership for Research on Ebola Virus in Liberia (PREVAIL), a collaboration between the government of Liberia and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Additional partners in the study include the National Eye Institute (NEI) and the National Institute of Neurological Disorders and Stroke (NINDS), both part of NIH; the University of Minnesota in Minneapolis; and the Johns Hopkins University Wilmer Eye Institute in Baltimore. The research is led by principal investigators Mosoka P. Fallah, Ph.D., deputy director general for technical services at the National Public Health Institute of Liberia, and Michael C. Sneller, M.D., medical officer at NIAID.
“The PREVAIL study has yielded novel insight regarding the health issues facing some survivors of Ebola virus disease in Liberia and their close contacts,” said NIAID Director Anthony S. Fauci, M.D. “We thank our partners in the Liberian government for their collaboration in the successful implementation of this study, and we thank the study volunteers for their selfless participation in this important research.”
PREVAIL initiated the study of Ebola survivors (called PREVAIL 3) in Liberia to determine the long-term consequences of EVD by comparing health outcomes in survivors (966 people) and a control group of uninfected household and community contacts (2,350 people). Participants in the study completed a baseline clinic visit in 2015 and are being reevaluated every six months for five years. Study sites include the John F. Kennedy Medical Center in Monrovia, the C.H. Rennie Hospital in Kakata, and Duport Road Clinic in Paynesville.
The newly published report compares health outcomes in survivors and contacts during their first year of study participation. Both survivors and controls self-reported a range of symptoms. However, survivors reported certain symptoms at significantly higher rates than controls, and in both groups, adults reported more symptoms than children and adolescents. Survivors reported higher rates of: urinary frequency (14.7 percent vs. 3.4 percent), headache (47.6 percent vs. 35.6 percent), fatigue (18.4 percent vs. 6.3 percent), muscle pain (23.1 percent vs. 10.1 percent), memory loss (29.2 percent vs. 4.8 percent), and joint pain (47.5 percent vs. 17.5 percent).
Evaluations by healthcare professionals showed significantly more survivors than controls had abnormal findings on abdominal (10.4 percent vs. 6.4 percent), chest (4.2 percent vs. 2 percent), and neurologic (4.5 percent vs. 1.5 percent) examinations. With regards to abnormal musculoskeletal findings on examination, only muscle tenderness was observed significantly more frequently in survivors than controls (4.5 percent vs. 0.9 percent, respectively). Other musculoskeletal findings, such as joint swelling and decreased range of motion were not observed at a significantly higher frequency in survivors compared with controls. The prevalence of health issues declined in both groups over the one-year follow-up period.
The investigators observed that health issues identified with physical evaluations were much less frequent than self-reported symptoms. They note that the self-reported symptoms were like those seen in people with post-infection syndromes. However, they say more research is needed to understand the origin, development, and progression of these self-reported symptoms. Study neurologists are currently following a subset of survivors and close contacts to better understand and characterize post-infection neurologic issues.
“The results from this study have a far-reaching public health and clinical care importance for Liberia, Africa, and world,” said Dr. Fallah. “The study further demonstrates the commitment of our survivors to this collaborative research between Liberia and the U.S.”
A subset of 564 survivors and 635 close contacts received eye exams by ophthalmologists at the John F. Kennedy Medical Center. At the baseline visit, 149 survivors (26.4 percent) had evidence of uveitis in at least one eye as compared with 77 participants in the control group (12.1 percent). Uveitis refers to a group of inflammatory eye diseases that can cause pain, redness, swelling, tissue damage, light sensitivity, and vision loss. Unlike other symptoms, the prevalence of uveitis increased in both groups at the one-year follow-up visit, with a significantly higher incidence of new cases among survivors compared to controls.
“Ebola-associated uveitis was common among our patients. This study highlights how crucial ophthalmic care is to the care of Ebola survivors,” said Rachel J. Bishop, M.D., M.P.H., chief of Consult Services at NEI and co-lead on the eye sub-study.
The prevalence of uveitis is consistent with previous findings in Ebola survivors. However, PREVAIL 3 also shows a high prevalence of uveitis in the control group suggesting that some Ebola survivors may have uveitis due to other diseases.
Despite the higher prevalence of uveitis in survivors, no differences in corrected visual acuity or age-adjusted prevalence of cataracts — clouding of the eye lens — were noted between survivors and controls either at baseline or at the one-year visit. The median vison in both survivors and contacts was 20/20, and the incidence of severe decreases in vision or blindness was similar in survivors and controls.
“Our findings underscore the importance of including population controls in a region where there are other causes of uveitis and cataracts,” said Dr. Sneller. “Systematic evaluations of participants and inclusion of a control group of people exposed to the same environment are critical to defining the true clinical sequelae of survivors of Ebola virus disease.”
Previous studies have indicated that fragments of Ebola virus RNA can persist in the semen of male survivors. The detection of Ebola virus genetic material in semen could indicate the presence of viable and potentially transmissible virus; however, it does not necessarily mean infectious virus exists. Reports describing cases of survivors transmitting Ebola virus to a sexual partner are rare, and more research is needed to understand the risks. As part of PREVAIL 3, 267 male survivor participants provided 2,416 semen samples, with 252 men providing more than one sample. Investigators detected viral RNA in one or more samples in 81 men (30 percent). The longest recorded time from EVD to detection of viral RNA in a sample was 40 months.
Interestingly, more than 30 men had two consecutive negative tests followed by one or more positive tests for Ebola virus RNA in semen. The findings indicate the existence of Ebola virus RNA in semen may be intermittent and more persistent than previously reported.
Investigators will continue to examine Ebola survivors and contacts to collect and analyze data for the remainder of the planned five-year study period. For more information about the trial, visit ClinicalTrials.gov and search identifierNCT02431923.
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
NEI leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.